Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue 2, 2012, Pages 79-87

  Diaz, Keith T ^a   Skaria, Shibu ^a   Harris, Keith ^a   Solomita, Mario ^a   Lau, Stephanie ^b   Bauer, Kristy ^b   Smaldone, Gerald C ^a   Condos, Rany ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clinical trial; inhaled therapy; nebulizer; scintigraphy

Indexed keywords

CARBON MONOXIDE; FIBROBLAST GROWTH FACTOR 2; FLT3 LIGAND; GAMMA1B INTERFERON; INTERLEUKIN 5; PERTECHNETIC ACID TC 99M; TECHNETIUM SULFUR COLLOID TC 99M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIFFUSING CAPACITY FOR CARBON MONOXIDE; DRUG SAFETY; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LUNG CAPACITY; LUNG LAVAGE; MALE; MEDICAL NEBULIZER; NEBULIZATION; SYSTEMIC DISEASE; TOTAL LUNG CAPACITY; VIRUS INHIBITION;

ADMINISTRATION, INHALATION; AEROSOLS; AGED; ANTIVIRAL AGENTS; BRONCHOALVEOLAR LAVAGE; CYTOKINES; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERFERON-GAMMA; MALE; MIDDLE AGED; PULMONARY DIFFUSING CAPACITY; RETROSPECTIVE STUDIES; TOTAL LUNG CAPACITY; VITAL CAPACITY;

EID: 84859418092     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0919     Document Type: Article

References (39)

1. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF, and Hunninghake GW: Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1994;149:450-454.
2. Douglas WW, Ryu JH, and Schroeder DR: Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med. 2000;161:1172-1178.
3. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, and Offord KP: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199-203.
4. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, and Kudoh S: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-1047.
5. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, and Montanari M: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2242.
6. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, and King TE Jr: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125-133.
7. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, and Fatenejad S: Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178:948-955.
8. Strieter RM and Mehrad B: New mechanisms of pulmonary fibrosis. Chest. 2009;136:1364-1370.
9. King TE Jr., Pardo A, and Selman M: Idiopathic pulmonary fibrosis. Lancet. 2011.
10. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208:1339-1350.
11. Strieter RM: What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc. 2008;5:305-310.
12. Homer RJ, Elias JA, Lee CG, and Herzog E: Modern concepts on the role of inflammation in pulmonary fibrosis. Arch Pathol Lab Med. 2011;135:780-788.
13. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, and du Bois RM: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374:222-228.
14. Strieter RM, Starko KM, Enelow RI, Noth I, and Valentine VG: Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2004;170:133-140.
15. Jaffe HA, Buhl R, Mastrangeli A, Holroyd KJ, Saltini C, Czerski D, Jaffe HS, Kramer S, Sherwin S, and Crystal RG: Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon- gamma to the human lung. J Clin Invest. 1991;88:297-302.
16. Condos R, Hull FP, Schluger NW, Rom WN, and Smaldone GC: Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis. Chest. 2004;125:2146-2155.
17. Raju B, Hoshino Y, Kuwabara K, Belitskaya I, Prabhakar S, Canova A, Gold JA, Condos R, Pine RI, Brown S, Rom WN, and Weiden MD: Aerosolized gamma interferon (IFN-.gamma) induces expression of the genes encoding the IFNgamma- inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect Immun. 2004;72:1275-1283.
18. Dawson R, Condos R, Tse D, Huie ML, Ress S, Tseng CH, Brauns C, Weiden M, Hoshino Y, Bateman E, and Rom WN: Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One. 2009;4:e6984.
19. Smaldone GC: Physiological and pathological considerations for aerosol deposition: expiration and models of deposition. J Aerosol Med. 2000;13:387-391.
20. Bennett WD and Smaldone GC: Human variation in the peripheral air-space deposition of inhaled particles. J Appl Physiol. 1987;62:1603-1610.
21. Nikander K, Prince I, Coughlin S, Warren S, and Taylor G: Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):S37-S43.
22. Skaria S, Smaldone GC, Omron NE: U22: Comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv 2010;23:173-180.
23. Nikander K, Arheden L, Denyer J, Cobos N: Parents adherence with nebulizer treatment of their children when using an adaptive aerosol delivery (AAD) system. J Aerosol Med 2003;16:273-281.
24. Solomita M and Smaldone GC: Reconciliation of cascade impaction during wet nebulization. J Aerosol Med Pulm Drug Deliv. 2009;22:11-18.
25. ORiordan TG, Greco MJ, Perry RJ, and Smaldone GC: Nebulizer function during mechanical ventilation. Am Rev Respir Dis. 1992;145:1117-1122.
26. McPeck M, Tandon R, Hughes K, and Smaldone GC: Aerosol delivery during continuous nebulization. Chest. 1997;111:1200-1205.
27. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med. 2000;161:646-664.
28. Bender R and Lange S: Adjusting for multiple testing-when and how? J Clin Epidemiol. 2001;54:343-349.
29. Spencer LT, Humphries JE, and Brantly ML: Antibody response to aerosolized transgenic human alpha1-antitrypsin. N Engl J Med. 2005;352:2030-2031.
30. Porter S: Human immune response to recombinant human proteins. J Pharm Sci. 2001;90:1-11.
31. Sangwan S, Condos R, and Smaldone GC: Lung deposition and respirable mass during wet nebulization. J Aerosol Med. 2003;16:379-386.
32. Wynn TA: Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4:583-594.
33. Hoffmann KF, Cheever AW, and Wynn TA: IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol. 2000;164: 6406-6416.
34. Gharaee-Kermani M and Phan SH: Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 1997;16:438-447.
35. Gharaee-Kermani M, McGarry B, Lukacs N, Huffnagle G, Egan RW, and Phan SH: The role of IL-5 in bleomycininduced pulmonary fibrosis. J Leukoc Biol. 1998;64:657-666.
36. Hetzel M, Bachem M, Anders D, Trischler G, and Faehling M: Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung. 2005;183:225-237.
37. Khalil N, Xu YD, OConnor R, and Duronio V: Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem. 2005;280:43000-43009.
38. Wodnar-Filipowicz A: Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow. News Physiol Sci. 2003;18:247-251.
39. Ley B, Collard HR, and King TE Jr: Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431-440